SCHEMBL4890552

SCHEMBL4890552

O=C(O)c1cccc(-c2nccc(C3=COC=C(C4=CC=CCC4)O3)n2)c1

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PIK3CD O00329 2/20 0.36
PIK3CA P42336 2/20 0.36
NPC1 O15118 2/20 0.36
RAB9A P51151 2/20 0.36
L3MBTL1 Q9Y468 1/20 0.36
ABL1 P00519 1/20 0.35
BCR P11274 1/20 0.35
PRKCA P17252 1/20 0.35
MAOA P21397 1/20 0.35
BLVRB P30043 1/20 0.35
HDAC6 Q9UBN7 1/20 0.35
KMO O15229 5/20 0.34
KEAP1 Q14145 1/20 0.34
NR1H4 Q96RI1 1/20 0.33
KDM4E B2RXH2 1/20 0.33
MEN1 O00255 1/20 0.33
POLB P06746 1/20 0.33
MAPT P10636 1/20 0.33
KMT2A Q03164 1/20 0.33
SMN1; SMN2 Q16637 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4890597 0.89 MAP4K4 (0.36) PIK3CDPIK3CANPC1RAB9AKDM4E
SCHEMBL15451326 0.77 BRD4 (0.34) NPC1RAB9A
SCHEMBL186575 0.74 NPC1 (0.41) NPC1RAB9AL3MBTL1KMOKEAP1
SCHEMBL3222942 0.73 KDM4E (0.46) NPC1RAB9AL3MBTL1KDM4EMEN1
SCHEMBL3592782 0.71
SCHEMBL4249062 0.71 DHODH (0.35) NPC1RAB9AL3MBTL1KDM4EPOLB
SCHEMBL3616817 0.70 MAPKAPK2 (0.35)
SCHEMBL4901056 0.68 MAPK8 (0.57) NPC1RAB9AABL1BCRPRKCA
SCHEMBL619635 0.68
SCHEMBL979608 0.68 MAOA (0.33) MAOA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9315467-B2 Compounds for nonsense suppression, and methods for their use PTC THERAPEUTICS, INC. (US) 2016-04-19 US disclosed
US-20080119473-A1 Compounds for Nonsense Suppression, and Methods for Their Use PTC THERAPEUTICS, INC. 2008-05-22 US disclosed
EP-1799212-A2 COMPOUNDS FOR NONSENSE SUPPRESSION, AND METHODS FOR THEIR USE PTC Therapeutics, Inc. (US) 2007-06-27 EP disclosed
WO-2006044505-A2 COMPOUNDS FOR NONSENSE SUPPRESSION, AND METHODS FOR THEIR USE PTC THERAPEUTICS, INC. (US) 2006-04-27 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080119473-A1 Compounds for Nonsense Suppression, and Methods for Their Use NSUN2, UPF1, NSUN3 PIK3CD 4038/4885PIK3CA 3058/4885NPC1 732/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.